A survey of North American VCs reveals that founders who adapt to evolving investor strategies are well-positioned to raise capital despite a market slowdown.
(Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the ...